Insulin glargine biosimilar (Biocon)

甘精胰岛素生物类似药 (Biocon)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin glargine biosimilar (Biocon)
Drug Alias NameInsulin glargine biosimilar (Biocon/Mylan)甘精胰岛素生物仿制药 (Biocon/Mylan)insulin glargine biosimilarSemgleeBasalog +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2009/01/01
Country/TerritoryUnited StatesSlovakiaTaiwan +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMylan NvFujifilm CorpBiocon Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesFujifilm CorpMylan Pharmaceuticals IncViatris Ltd
Inactive CompaniesMylan IncBiocon LtdMylan Gmbh
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AE04
Related LinksN/A